Biosimilars: Concept and Regulation

View Sample PDF

Author(s): Anil K. Sharma (GD Goenka University, India), Raj K. Keservani (Rajiv Gandhi Proudyogiki Vishwavidhyalaya, India)and Rajesh K. Kesharwani (Nims University Rajasthan, India)
Copyright: 2017
Pages: 18
Source title: Novel Approaches for Drug Delivery
Source Author(s)/Editor(s): Raj K. Keservani (Rajiv Gandhi Proudyogiki Vishwavidyalaya, India), Anil K. Sharma (GD Goenka University, India)and Rajesh Kumar Kesharwani (National Institute of Technology, Warangal, India)
DOI: 10.4018/978-1-5225-0751-2.ch007

Keywords: Medical Information Science Reference / Medicine & Healthcare / Pharmacology

Purchase

View Biosimilars: Concept and Regulation on the publisher's website for pricing and purchasing information.

Abstract

Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in coming years. The main aim of present article is to introduce the fundamentals of biologics and to explain how they are different and what these differences mean for pharmacists.

The IRMA Community

Research IRM

Biosimilars: Concept and Regulation

Purchase

Abstract

Related Content

IRMA Sponsors